1 Response to combination antiretroviral therapy: variation by age. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study group.
AIDS. 22(12):1463-1473, July 31, 2008
2 Incidence and risk factors of HIV-related non-Hodgkin lymphoma in the era of combination antiretroviral therapy: European multi-cohort study.The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group.
Antiviral Ther. 2009; 14(8):1065-74 article
3 Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group AIDS. 2009 Sep 24;23(15):2029-37.
4 Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: Collaborative analysis of 13 HIV cohort studies. The Antiretroviral Therapy Cohort Collaboration Study Group (ART-CC).
Clin Infect Dis. 2010 May 15;50(10):1387-96. abstract
5 Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HV infection and a CD4 cell count <200 cells/mL? The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE).
Clinical Infectious Diseases. 2010;51(5):000-000. article
6 Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), R Lodwick, D Costagliola, P Reiss, C Torti, R Teira, M Dorrucci, B Ledergerber, A Mocroft, D Podzamczer, A Cozzi-Lepri, N Obel, B Masquelier, S Staszewski, F García, S De Wit, A Castagna, A Antinori, A Judd, J Ghosn, G Touloumi, C Mussini, X Duval, J Ramos, L Meyer, J Warsawski, C Thorne, J Masip, S Pérez-Hoyos, D Pillay, A van Sighem, S Lo Caputo, H Günthard, R Paredes, A De Luca, D Paraskevis, C Fabre-Colin, J Kjaer, G Chêne, JD Lundgren, AN Phillips.
Arch Intern Med. 2010 Mar 8;170(5):410-9. abstract
7 HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T cell lymphocytes. J Bohlius, K Schmidlin, F Boué, G Fätkenheuer, M May, AM Caro-Murillo, A Mocroft, F Bonnet, G Clifford, V Paparizos, JM Miro, N Obel, M Prins, G Chêne, M Egger.
Blood. 2011 Jun 9;117(23):6100-8.
8 Impact of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy - a European multi-cohort study. The EuroCoord-CHAIN joint project. L Wittkop, HF Günthard, F de Wolf, D Dunn, A Cozzi-Lepri, A de Luca, C Kucherer, N Obel, V von Wyl, B Masquelier, C Stephan, C Torti, A Antinori, F Garcia, A Judd, K Porter, R Thiébaut, H Castro (née Green), AI van Sighem, C Colin, J Kjær, JD Lundgren, R Paredes, A Pozniak, B Clotet, A Phillips, D Pillay, G Chêne.
Lancet Infectious Diseases. 2011 May;11(5):363-371. Epub 2011 Feb 25.
9 Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), H Castro, A Judd, DM Gibb, K Butler, RL Lodwick, A van Sighem, JT Ramos, J Warsawski, C Thorne, A Noguera-Julian, N Obel, D Costagliola, PA Tookey, C Colin, J Kjær, J Grarup, G Chene, A Phillips.
Lancet. 2011 May 7;377(9777):1580-7.
10 Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. D Costagliola for the PLATO II group for COHERE in EuroCoord.
Lancet Infectious Diseases. 2012 Feb; 12(2):119-27. abstract
11 Calendar time trends in the incidence and prevalence of triple-class viroligic failure in antiretroviral drug experienced people with HIV in Europe. F Nakagawa for the PLATO II group for COHERE in EuroCoord.
JAIDS. 2012 Mar 1;59(3):294-9. abstract
12 CD4 cell count and the risk of AIDS or death in HIV-infected adults on cART with a suppressed viral load: A longitudinal cohort study from COHERE. J Young, M Psichogiou, L Meyer, S Ayayi, S Grabar, F Raffi, P Reiss, B Gazzard, M Sharland, F Gutierrez, N Obel, O Kirk, JM Miro, H Furrer, A Castagna, S De Wit, J Muñoz, J Kjær, C Colin, J Grarup, G Chêne, H Bucher.
PLoS Med. 2012 Mar;9(3):e1001194.
13 All-cause mortality in treated HIV-infected adults with CD4 >=500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. C Lewden, V Bouteloup, S De Wit, C Sabin, A Mocroft, JC Wasmuth, A van Sighem, O Kirk, N Obel, G Panos, J Ghosn, F Dabis, M Mary-Krause, C Leport, S Perez-Hoyos, P Sobrino-Vegas, C Stephan, A Castagna, A Antinori, A d'Arminio Monforte, C Torti, C Mussini, V Isern, A Calmy, R Teira, M Egger, J Grarup, G Chêne.
Int J Epidemiol. 2012 Apr;41(2):433-445.
14 Effect of hepatitis C treatment on CD4 cell counts and the risk of death in HIV-hepatitis C co-infected patients; COHERE collaboration. Hepatitis working group for COHERE in EuroCoord.
Antivir Ther. 2012;17(8):1541-50.
15 Predictors of CD4 cell counts of HIV-1-infected persons after virologic failure to all three original antiretroviral drug classes. The Pursuing Later Treatment Option II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group.
J Infect Dis. 2013 Mar 1;207(5):759-67.
Updated: 09 Apr 2013